Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Neurocrine Biosciences Inc.

Neurocrine ( ($NBIX) ) has provided an announcement. At its Annual Meeting on May 27, 2026, Neurocrine stockholders elected three Class III directo...

Neurocrine Shareholders Reelect Directors and Approve Governance Measures

Neurocrine Biosciences ($NBIX) announced an update on their ongoing clinical study. Neurocrine Biosciences is running a Phase 2 study called “A Pha...

Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eledon Pharmaceuticals (ELDN), Neurocrine (NBIX) and...

Market Cap	$15.45B	P/E Ratio	23.08
52W High	$162.39	52W Low	$119.62
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	44.0%	52W Position	106.7%
Overall Score	69	Value Score	70
Quality Score	71	Technical Score	66

EPS Current Est	$7.16	EPS Next Est	$9.42
EPS Growth Est	+31.6%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NBIX	$165.24	+1.30%	1.10M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NBIX	$165.24	+1.3%	1.10M
3
4
5
6

NBIX

NBIX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Neurocrine Biosciences Inc. Data in Excel

Get Neurocrine Biosciences Inc. Data in Excel